L
LifeMine Therapeutics
Pioneering in genomically-enabled drug discovery approach integrating advanced life science and computational technologies
About LifeMine Therapeutics
LifeMine Therapeutics is a pioneering startup that is revolutionizing the field of drug discovery by harnessing the power of nature. The company is focused on mining genetically-encoded small molecules (GEMs) from the biosphere, which are potential solutions to some of the most challenging medical problems. LifeMine operates in the pharmaceutical industry, serving patients in need of innovative and transformative medicines.
The company's business model is centered on its unique drug discovery engine, which integrates advanced technologies like gigascale DNA sequencing, artificial intelligence, and synthetic biology. This engine allows LifeMine to explore the vast biological space digitally, leading to the discovery of novel medicines that can tackle previously untreatable diseases.
LifeMine's primary source of revenue is expected to come from the commercialization of these newly discovered drugs. The company has successfully decoded an evolutionary code in biosynthetic genes, which has paved the way for the rapid discovery of naturally inspired drugs that work in unexpected ways. These drugs go beyond the standard playbook of drug design, offering new hope for patients.
LifeMine's approach is particularly focused on fungi, which are known to be a rich source of impactful medicines due to their evolutionary proximity to humans. The company has built a comprehensive fungal genome repository, which it uses to search for new GEMs. Despite the challenges associated with discovering these GEMs, LifeMine's innovative approach has opened up a new pathway to uncover these hidden therapeutic solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 63.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biochemical, Core AI, Synthetic Biology, Rumoured $1B, Biotech and Pharma, AI Drug Discovery, AI Applications
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2022 | $175M | $700M | GSK · Fidelity Investments | ↗ |
| SERIES BOther financing | Jan 2021 | $50M | $200M | Undisclosed | — |
Growth signals
Latest recorded traffic for LifeMine Therapeutics is 3.4K monthly website visits, up 126.7% over the last three months. LifeMine Therapeutics's team declined 8.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
GV
Boyu Capital
M Ventures
Alexandria Venture Investments
Blue Pool Capital
Foresite Capital
ARCH Venture Partners
WuXi Healthcare Ventures
Series B and later2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LifeMine Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LifeMine Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









